The Codon Capital Approach
It is easy to predict the future of biotechnology, but it is difficult to know who will invent it, what business success it will fuel. How long will it take? What are the key obstacles that stopped others before, where we see a path (or better: multiple paths) forward to a new innovative technology. Codon Capital knows how to recognize the what ifs with a technical path that enable breakthrough products.
Therapeutics
Investment FocusInnovation Meeting Unmet Medical Needs
|
Synthetic Biology
Investment FocusBetter, Faster, Cheaper Biology
|
START-UP ECOSYSTEM
|
YEARS COMBINED BIOTECH
VENTURE EXPERIENCE IPOs
COMPANIES EXITED FROM SEED or SERIES A
IN LESS THAN 18 MONTHS |
27 Investments
|
Amplyx Pharmaceuticals • Antheia • Araxes Pharma • Arcus Biosciences • Avidity Biosciences • Bolt Threads • Caribou Biosciences • Clear Labs • eGenesis • EpiBiome • Flexus Biosciences • Glycostasis • Good Therapeutics • Jasper Therapeutics • Kumquat Biosciences • Kura Oncology • Oric Pharmaceuticals • Pivot Bio • RAPT Therapeutics • Shattuck Labs • Vaxart • ViewPoint Therapeutics • Zephyrus Biosciences • Zymergen
|
About Codon
Codon Capital is a San Francisco-based biotech venture capital company, specializing in therapeutics and synthetic biology. Our investment approach is to fund startup teams that can execute on difficult technical, definable achievements that enable breakthrough biotech products. We’re investing in solutions to the most critical problems of human health and sustainability, and in teams who can make the "impossible" possible.
Our early stage investments back teams to build enduring quality solutions, which sometimes are snapped up via acquisitions, but also have the option to raise additional equity at attractive valuations to seek even more value.
Our early stage investments back teams to build enduring quality solutions, which sometimes are snapped up via acquisitions, but also have the option to raise additional equity at attractive valuations to seek even more value.
